AbCellera Investor Conference Presentation Deck

JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT © ABCELLERA 9 OUR PIPELINE - ABCL635 A potential first-in-class antibody therapy for metabolic and endocrine conditions. ABCL635 is the first AbCellera-led asset derived from our GPCR and ion channel platform. Molecule Status Target MOA Indication Therapeutic Area Market Opportunity Potential Differentiation Summary ABCL635 IND-enabling studies (Preclinical) Undisclosed - GPCR or ion channel Antagonist Undisclosed Metabolic & endocrine conditions >$2B First-in-class Program details and indication will only be disclosed once the molecule reaches the clinic.

View entire presentation